JP7595004B2 - 甲状腺ホルモン受容体ベータアゴニスト化合物 - Google Patents

甲状腺ホルモン受容体ベータアゴニスト化合物 Download PDF

Info

Publication number
JP7595004B2
JP7595004B2 JP2021519726A JP2021519726A JP7595004B2 JP 7595004 B2 JP7595004 B2 JP 7595004B2 JP 2021519726 A JP2021519726 A JP 2021519726A JP 2021519726 A JP2021519726 A JP 2021519726A JP 7595004 B2 JP7595004 B2 JP 7595004B2
Authority
JP
Japan
Prior art keywords
substituted
compound
alkyl
methyl
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021519726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504620A5 (https=
JP2022504620A (ja
JPWO2020077123A5 (https=
Inventor
トーステン・エイ・カーシュバーグ
ランドール・ハルコム
インジー・シュー
エフ・アンソニー・ロメロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Inc
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of JP2022504620A publication Critical patent/JP2022504620A/ja
Publication of JP2022504620A5 publication Critical patent/JP2022504620A5/ja
Publication of JPWO2020077123A5 publication Critical patent/JPWO2020077123A5/ja
Priority to JP2024204381A priority Critical patent/JP2025041602A/ja
Application granted granted Critical
Publication of JP7595004B2 publication Critical patent/JP7595004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021519726A 2018-10-12 2019-10-10 甲状腺ホルモン受容体ベータアゴニスト化合物 Active JP7595004B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024204381A JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745195P 2018-10-12 2018-10-12
US62/745,195 2018-10-12
PCT/US2019/055689 WO2020077123A1 (en) 2018-10-12 2019-10-10 Thyroid hormone receptor beta agonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024204381A Division JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Publications (4)

Publication Number Publication Date
JP2022504620A JP2022504620A (ja) 2022-01-13
JP2022504620A5 JP2022504620A5 (https=) 2022-10-13
JPWO2020077123A5 JPWO2020077123A5 (https=) 2022-10-13
JP7595004B2 true JP7595004B2 (ja) 2024-12-05

Family

ID=70161488

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519726A Active JP7595004B2 (ja) 2018-10-12 2019-10-10 甲状腺ホルモン受容体ベータアゴニスト化合物
JP2024204381A Pending JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024204381A Pending JP2025041602A (ja) 2018-10-12 2024-11-25 甲状腺ホルモン受容体ベータアゴニスト化合物

Country Status (10)

Country Link
US (2) US11203587B2 (https=)
EP (1) EP3863635A4 (https=)
JP (2) JP7595004B2 (https=)
CN (1) CN112839655B (https=)
AR (1) AR116694A1 (https=)
AU (1) AU2019357618B2 (https=)
CA (1) CA3114015A1 (https=)
MA (1) MA53868A (https=)
TW (2) TWI840423B (https=)
WO (1) WO2020077123A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
GEP20247637B (en) 2019-05-08 2024-06-25 Aligos Therapeutics Inc Modulators of thr-b and methods of use thereof
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
US20230257367A1 (en) * 2020-06-02 2023-08-17 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone beta receptor agonist
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CA3212130A1 (en) * 2021-03-03 2022-09-09 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114768A (ja) 1999-09-30 2001-04-24 Pfizer Prod Inc 甲状腺受容体リガンドとしての６−アザウラシル誘導体
JP2009501759A (ja) 2005-07-21 2009-01-22 エフ．ホフマン−ラ ロシュ アーゲー 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体
JP2011528007A (ja) 2008-07-15 2011-11-10 ピエール、ファーブル、メディカマン トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用
JP2017525740A (ja) 2014-09-05 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
US7230031B2 (en) 2002-01-30 2007-06-12 Kissei Pharmaceutical Co., Ltd. Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
TWI534144B (zh) 2009-04-20 2016-05-21 田邊三菱製藥股份有限公司 甲狀腺荷爾蒙β受體作動藥
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EP2780338B1 (en) * 2011-11-14 2016-11-09 Ignyta, Inc. Uracil derivatives as axl and c-met kinase inhibitors
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
IL266054B2 (en) 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
CN111801324B (zh) 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
CA3110520A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US12391677B2 (en) 2018-10-12 2025-08-19 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
US12338206B2 (en) 2019-02-21 2025-06-24 Nanjing Ruijie Pharma Co., Ltd. Compounds and their uses as thyroid hormone receptor agonists
CN114174282A (zh) 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114768A (ja) 1999-09-30 2001-04-24 Pfizer Prod Inc 甲状腺受容体リガンドとしての６−アザウラシル誘導体
JP2009501759A (ja) 2005-07-21 2009-01-22 エフ．ホフマン−ラ ロシュ アーゲー 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体
JP2011528007A (ja) 2008-07-15 2011-11-10 ピエール、ファーブル、メディカマン トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用
JP2017525740A (ja) 2014-09-05 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用

Also Published As

Publication number Publication date
CA3114015A1 (en) 2020-04-16
CN112839655B (zh) 2025-11-25
AR116694A1 (es) 2021-06-02
TWI884745B (zh) 2025-05-21
JP2025041602A (ja) 2025-03-26
US20200115362A1 (en) 2020-04-16
JP2022504620A (ja) 2022-01-13
EP3863635A1 (en) 2021-08-18
MA53868A (fr) 2021-08-18
US20220348561A1 (en) 2022-11-03
US11203587B2 (en) 2021-12-21
TWI840423B (zh) 2024-05-01
AU2019357618A1 (en) 2021-04-29
TW202027748A (zh) 2020-08-01
WO2020077123A1 (en) 2020-04-16
CN112839655A (zh) 2021-05-25
TW202430520A (zh) 2024-08-01
AU2019357618B2 (en) 2025-04-24
EP3863635A4 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
JP7595004B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
JP7846735B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
EP3555070B1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
JP7646632B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
TWI826525B (zh) 用於治療特定白血病之化合物
JP7187449B2 (ja) Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物
JP2023539275A (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
CA3212130A1 (en) Thyroid hormone receptor beta agonist compounds
CA3144366A1 (en) Compounds for inhibiting fgfr4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241125

R150 Certificate of patent or registration of utility model

Ref document number: 7595004

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150